System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Maria Vieito is an expert in Oncology at Vall d'Hebron Hospital Universitari (Spain). As of October 2026, ScienceLeadR ranks Maria Vieito in the top 1% of experts worldwide for Glioma. Maria Vieito has authored 163 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 14 of them ongoing. SLR score: 1,136 (community average: 125). How the SLR is computed.

LeadR Profile

Maria Vieito Vall d'Hebron Hospital Universitari Spain
1 136 ScienceLeadR Reputation 1136

Unlock

Register Login
Network Map

Oncology

Subspecialties: Neurology - Biochemistry - Medical Imaging

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Vall d'Hebron Hospital Universitari

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 163

Citations

Citations: 2 008 1st author: 20 Last author: 12 Unique author: 0

Main journals

J Clin Oncol 28
Ann Oncol 19
Neuro Oncol 12
Eur J Cancer 8
Clin Transl Oncol 5

Best Journals

J Clin Oncol 19
Ann Oncol 18
Nat Med 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.
PMID 42826365 — safety, melanoma, neoplasms, precision medicine, therapeutics		JCO Precis Oncol20260
Clinical trial design for primary brain tumors: a problem-based framework for neuro-oncology practice.
PMID 42756914 — brain neoplasms, brain, neoplasms, uncertainty, glioblastoma, steroids		Front Oncol20260
Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib Study.
PMID 42659589		J Clin Oncol Top journal20260
Regulatory delay and lost opportunity in IDH-mutant low-grade glioma.
PMID 42474656 — glioma, neoplasms		Clin Transl Oncol20260
Correction: Needs and health-related quality of life domains relevant to people in Europe with advanced cancer in need of palliative care: a systematic review of qualitative research.
PMID 42412365 — quality of life, neoplasms, rehabilitation, research, therapeutics, palliative care, qualitative research		Qual Life Res20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 1 13
Phase 3 6
Phase 1/Phase 2 4
Phase 2 4
N/A 2
Phase 2/Phase 3 1

By status:

Recruiting 8
Active not recruiting 7
Completed 6
Terminated 6
Not yet recruiting 2
Unknown 1

By type:

Interventional 29
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 1
multicentric5to9 3
multicentricup10 23

Main Topics

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High grade Glioma a Window of Opportunity Study (TARLAGLIA Study)
NCT07788677 — glioma, safety, neoplasms, drug-related side effects and adverse reactions, therapeutics, infusions, intravenous		Phase 1Not yet recruiting2026
A phase I open label multi center study to evaluate the safety tolerability dosimetry and preliminary activity of 177Lu Lu DFC413 and safety and imaging properties of 68Ga Ga NNS309 in patients with solid tumors
2025-521702-18-00 — safety, neoplasms, multiple chronic conditions		Phase 1Recruiting2026
A Phase 1 Open Label Multicenter Study of INCA033890 in Participants with Advanced or Metastatic Solid Tumors
2022-502456-31-00 — neoplasms		Phase 1Recruiting2023
A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields) together with temozolomide and pembrolizumab compared to Optune (Tumor Treating Fields) together with temozolomide and placebo (ie inactive substance)
2024-513550-30-00 — research design, temozolomide, neoplasms, maintenance, glioblastoma, therapeutics		Phase 3Recruiting2025
Tuvusertib in Astrocytoma With ATRX Mutation
NCT07417761 — safety, astrocytoma, neoplasms, therapeutics, mutation		Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS